ANI Pharmaceuticals, Inc. (ANIP)
- Previous Close
66.14 - Open
66.03 - Bid 65.22 x 100
- Ask 65.47 x 100
- Day's Range
65.15 - 66.19 - 52 Week Range
37.06 - 70.81 - Volume
82,409 - Avg. Volume
145,250 - Market Cap (intraday)
1.373B - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
76.98 - EPS (TTM)
0.85 - Earnings Date May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
79.80
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
www.anipharmaceuticals.com642
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ANIP
Performance Overview: ANIP
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANIP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANIP
Valuation Measures
Market Cap
1.37B
Enterprise Value
1.46B
Trailing P/E
76.98
Forward P/E
14.41
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.45
Price/Book (mrq)
3.17
Enterprise Value/Revenue
3.00
Enterprise Value/EBITDA
13.72
Financial Highlights
Profitability and Income Statement
Profit Margin
3.86%
Return on Assets (ttm)
3.72%
Return on Equity (ttm)
4.72%
Revenue (ttm)
486.82M
Net Income Avi to Common (ttm)
15.47M
Diluted EPS (ttm)
0.85
Balance Sheet and Cash Flow
Total Cash (mrq)
221.12M
Total Debt/Equity (mrq)
63.67%
Levered Free Cash Flow (ttm)
112.78M
Research Analysis: ANIP
Company Insights: ANIP
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ANIP
ANIP: What does Argus have to say about ANIP?
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $69.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetANIP: Lowering target price to $69.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $69.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetANIP: What does Argus have to say about ANIP?
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $70.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetANIP: Lowering target price to $70.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $70.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target